Allergan is still on the acquisition trail following its failed merger with Pfizer, spending $85 million to acquire privately-held Topokine Therapeutics and its late-stage product for under-eye bags.

Allergan has bought the privately-held biotech Bonti, which has been developing a fast-acting, short duration replacement alternative to Botox ahead of potentially cheaper competition from a ...